arXiv:2606. 11144v1 Announce Type: new Abstract: Resistance to first-line osimertinib in EGFR-mutant non-small-cell lung cancer (NSCLC) is the canonical example of predictable clonal evolution under therapeutic pressure, yet no public benchmark exists for training or evaluating computational models on the corresponding longitudinal patient trajectories.
By Abhijoy Sarkar, Aarchi Singh Thakur
arXiv:2608. 05359v1 Announce Type: new Abstract: CASCADE is an agentic framework that predicts downstream transcriptional effects of gene perturbation from precomputed ARACNe regulatory networks, exposed via MCP.
By Jose A. Bird
arXiv:2606. 17491v1 Announce Type: cross Abstract: Binary data factorization is common, but real-valued methods ignore discreteness and yield hard-to-interpret factors.
By Adolphus Wagala, Mehmet Samur, Giovanni Parmigiani
arXiv:2608. 07609v1 Announce Type: cross Abstract: High-throughput screening (HTS) assays are central to early-stage drug discovery but are often limited by extreme data sparsity, as primary screens typically use only a single replicate per test substance.
By Xiaohua Douglas Zhang
arXiv:2607. 02768v1 Announce Type: cross Abstract: Pathologic complete response and tumor shrinkage measure whether breast cancer responds to neoadjuvant therapy, but not whether that response was structurally favorable, persistent, or hidden beneath volume loss.
By Dattatreya Kantha, Murray H. Loew
arXiv:2607. 10466v1 Announce Type: new Abstract: Survival models can model time-to-event outcomes using partially observed data.
By Yanqi Xu, Hui Dai, Carlos Fernandez-Granda, Krzysztof J. Geras, Yiqiu Shen